Bruton's Tyrosine Kinase (BTK) Inhibitors - Pipeline Insights 2017

The “Bruton's Tyrosine Kinase (BTK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of Bruton's tyrosine kinase (BTK) drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Bruton's tyrosine kinase (BTK) inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the analysis on active pipeline molecules; the report also provides detailed information about discontinued and dormant drugs.

View report: https://www.arizton.com/reports/pharma-pipeline-analysis/brutons-tyrosine-kinase-btk-inhibitors-pipeline

The report profiles key players in developing potential BTK drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Currently, marketed anti-BTK drug is Imbruvica (ibrutinib). It is indicated for the treatment of graft versus host disease, hematological malignancies, and Non-Hodgkin’s lymphoma.

Pipeline activity of BTK inhibitors is quite dynamic. Several BTK inhibitors candidates more than 20 are in late stage clinical trials and are expected to achieve the regulatory approval in the near future which includes GDC-0834, GDC-0834, RN486, TP-4207, PCI-45261, BGB-3111, PCI 45292, ABBV-105, PRN1008, HCI-1401, EBI-1367, EBI-1266, SNS-062, RG7845, and GDC-0853. Preclinical and early clinical results indicate that these inhibitors are useful for the treatment of lymphomas and leukemias. The companies which are involved in the development of BTK inhibitors are Gilead, Roche, AbbVie, J&J, Eli Lilly, AstraZeneca, and Biogen.

Reasons to Buy

To gain erudite insights about the Bruton's tyrosine kinase (BTK) inhibitors pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

Related Reports

1) AKT Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/akt-inhibitors-pipeline

2) Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/anaplastic-lymphoma-kinase-alk-inhibitors-pipeline-insights

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.